Also reported were the results of a study evaluating outcomes of persons at high risk for lung cancer who were referred for and underwent LDCT lung cancer screening at a comprehensive cancer center.
Of the 485 participants who underwent lung cancer screening over a 3-month period, LDCT findings were categorized as negative, probably benign, and requiring additional testing in 74%, 5%, and 8%, respectively. Of the 39 patients included in the latter category, stage I/II, stage III, and stage IV lung cancer were diagnosed in 6, 1, and 1 participant(s), respectively.
“Lung cancer screening with [LDCT] detects lung cancer in earlier stages and reduces mortality,” Dr Howard emphasized in her closing remarks.
1. Howard C. Lung cancer screening. Presented at: ONS Bridge; September 8-17, 2020. Accessed September 4, 2020. https://ons.confex.com/ons/2020/ap/eposter.cgi?eposterid=1049
2. National Lung Screening Trial Research Team; Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395-409. doi:10.1056/NEJMoa1102873
3. U.S. Preventive Services Task Force. Final recommendation statement. Lung cancer: screening. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening. Accessed September 8, 2020.
4. Pham D, Bhandari S, Oechsli M, Pinkston CM, Kloecker GH. Lung cancer screening rates: data from the lung cancer screening registry. J Clin Oncol. 2018;36(15_suppl):Abstract 6504.
This article originally appeared on Oncology Nurse Advisor